Israel - English - Ministry of Health

rafa laboratories ltd - naloxone hydrochloride (as dihydrate); oxycodone hydrochloride - tablets prolonged release - oxycodone hydrochloride 10 mg; naloxone hydrochloride (as dihydrate) 5 mg - naloxone - naloxone - targin is indicated for the relief of moderate to severe pain.the oxycodone component is indicated for the relief of moderate to severe pain in adults who require continuous around-the-clock opioid analgesia for several days or more. the opioid antagonist naloxone is added to counteract opioid-induced constipation by blocking the action of oxycodone at opioid receptors locally in the gut.

Israel - English - Ministry of Health

rafa laboratories ltd - naloxone hydrochloride (as dihydrate); oxycodone hydrochloride - tablets prolonged release - oxycodone hydrochloride 20 mg; naloxone hydrochloride (as dihydrate) 10 mg - naloxone - naloxone - targin is indicated for the relief of moderate to severe pain.the oxycodone component is indicated for the relief of moderate to severe pain in adults who require continuous around-the-clock opioid analgesia for several days or more. the opioid antagonist naloxone is added to counteract opioid-induced constipation by blocking the action of oxycodone at opioid receptors locally in the gut

Israel - English - Ministry of Health

rafa laboratories ltd - naloxone hydrochloride (as dihydrate); oxycodone hydrochloride - tablets prolonged release - oxycodone hydrochloride 5 mg; naloxone hydrochloride (as dihydrate) 2.5 mg - naloxone - naloxone - targin is indicated for the relief of moderate to severe pain.the oxycodone component is indicated for the relief of moderate to severe pain in adults who require continuous around-the-clock opioid analgesia for several days or more. the opioid antagonist naloxone is added to counteract opioid-induced constipation by blocking the action of oxycodone at opioid receptors locally in the gut.

Israel - English - Ministry of Health

rafa laboratories ltd - naloxone hydrochloride (as dihydrate); oxycodone hydrochloride - tablets prolonged release - naloxone hydrochloride (as dihydrate) 20 mg; oxycodone hydrochloride 40 mg - naloxone - naloxone - targin is indicated for the relief of moderate to severe pain.the oxycodone component is indicated for the relief of moderate to severe pain in adults who require continuous around-the-clock opioid analgesia for several days or more. the opioid antagonist naloxone is added to counteract opioid-induced constipation by blocking the action of oxycodone at opioid receptors locally in the gut

Israel - English - Ministry of Health

rafa laboratories ltd - naloxone hydrochloride (as dihydrate); oxycodone hydrochloride - tablets prolonged release - naloxone hydrochloride (as dihydrate) 15 mg; oxycodone hydrochloride 30 mg - oxycodone and naloxone - targin is indicated for the relief of moderate to severe pain.the oxycodone component is indicated for the relief of moderate to severe pain in adults who require continuous around the- clock opioid analgesia for several days or more. the opioid antagonist naloxone is added to counteract opioid-induced constipation by blocking the action of oxycodone at opioid receptors locally in the gut.

Ireland - English - HPRA (Health Products Regulatory Authority)

mundipharma pharmaceuticals limited - oxycodone hydrochloride, naloxone hydrochloride - tablet prolonged release - 2.5 / 1.25 milligram - 02aa55

United States - English - NLM (National Library of Medicine)

purdue pharma lp - oxycodone hydrochloride (unii: c1enj2te6c) (oxycodone - unii:cd35pmg570), naloxone hydrochloride (unii: f850569pqr) (naloxone - unii:36b82amq7n) - targiniq er is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. limitations of use - because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations [see warnings and precautions (5.1)] , reserve targiniq er for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. - targiniq er is not indicated as an as-needed (prn) analgesic. - the maximum total daily dose of targiniq er should not exceed 80 mg/40 mg (40 mg/20 mg q12h) because higher doses may be associated with symptoms of opioid withdrawal or decreased analgesia [see warnings and precautions 5.12] . targiniq er is contraindicated in patients

Australia - English - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - naloxone hydrochloride; oxycodone hydrochloride -

Singapore - English - HSA (Health Sciences Authority)

dksh singapore pte. ltd. - naloxone 4.50mg eqv to naloxone hydrochloride anhydrous; oxycodone 9.00mg eqv oxycodone hydrochloride anhydrous - tablet, film coated, extended release - 5.00 mg/tablet - naloxone 4.50mg eqv to naloxone hydrochloride anhydrous 5 mg; oxycodone 9.00mg eqv oxycodone hydrochloride anhydrous 10 mg

Singapore - English - HSA (Health Sciences Authority)

mundipharma pharmaceuticals pte. ltd. - naloxone 9.00mg eqv naloxone hydrochloride anhydrous; oxycodone 18.00mg eqv oxycodone hydrochloride anhydrous - tablet, film coated, extended release - 10.00 mg/tablet - naloxone 9.00mg eqv naloxone hydrochloride anhydrous 10 mg; oxycodone 18.00mg eqv oxycodone hydrochloride anhydrous 20 mg